Randox pledges commitment to business in Europe
Global healthcare firm Randox Laboratories has pledged its commitment to maintaining and developing its business relationships with Europe, as a group of 20 representatives from the diagnostics company have travelled to Greece this week, to take part in one of Europe’s largest diagnostics conference in Athens.
EuroMedLab, which is run by the European Congress of Clinical Chemistry and Laboratory Medicine, is attended by thousands of healthcare professionals from across the globe, and offers Randox the opportunity to showcase their capabilities and to network with key decision makers.
Managing Director of Randox, Dr. Peter FitzGerald, commented on what the company hopes to achieve by attending EuroMedLab;
“We highly value the business we do within the European market and have successfully made a name for ourselves in the diagnostics industry in these countries. We already have a number of key sales offices and distribution centres in the likes of France, Germany, Portugal, Italy, Spain and Poland, but there is so much more we can do. Attending key networking events such as EuroMedLab is vital because it allows us the opportunity to meet with our existing customers and partners, to nurture and develop these relationships, and of course establish new ones.”
At the EuroMedLab conference the delegation team of Randox scientists, business development executives and market researchers will be making a series of announcements and presentations for new products including an innovative stroke diagnostic, newly discovered biomarkers for coronary heart disease risk, and the latest in laboratory quality assurance software.
The team will also present for the first time the Evidence Evolution analyser, a biochip testing platform capable of delivering accurate results from more than 2600 tests an hour including, but not exclusive to, cancer surveillance, fertility, heart, nutritional, digestive and diabetes health.
Dr. FitzGerald continued;
“At Randox we invest up to 16% of our turnover in R&D and we therefore have more new tests in development than any other diagnostics company in the world. This puts us in a very unique position in the market because our new developments, which are focused in areas where they are needed the most, successfully address the most urgent health issues.
“In light of recent political developments, there will of course be particular business challenges in Europe, but at Randox we will maintain our commitment to nurturing our relationships with key business partners in Europe and to seeking new opportunities in international markets such as the US.”
EuroMedLab runs from the 11th – 15th June 2017 at the Megaron Athens International Conference Centre in Athens. Randox can be found at booth #13 in the Skalkotas Hall Foyer.
Global biotechnology firm Randox is unveiling its latest, state-of-the-art laboratory technology at one of the biggest medical exhibitions in the world.
Randox, headquartered in County Antrim, is exhibiting at EuroMedLab in Paris, where it is launching its new clinical healthcare analyser; the RX misano, which will be exported to hospitals, veterinary clinics and teaching laboratories across the globe.
The machine; the latest of a range of equipment designed and manufactured by Randox, is attracting the attention of key international customers, across the world.
Graeme McNeill, Global Sales Manager at Randox says the new analyser has been developed to offer cutting-edge technology and functionality, typically associated with larger instruments, on a small footprint analyser.
“At Randox we have utilised our talents and experience in the life sciences, software development and engineering to create this pioneering technology, building on over a decade of R&D for this particular product range.
“The new RX misano shines a new light on semi-automated chemistry testing with its touch screen technology and here in Paris, we have had interest from Ministries of Health, leading clinics and research institutes around the world.”
Dr Peter FitzGerald, MD at Randox, says the company is proud to be promoting Northern Ireland’s innovation to an international audience:
“Randox is committed to improving healthcare worldwide and our clinical chemistry analysers are already in place in 120 countries; but this new machine is the next generation in Randox diagnostic capabilities. It will ensure that clinicians get the most reliable and accurate results and more quickly – allowing patients to be treated effectively and efficiently.
“The RX misano is the epitome of our ambition, our innovation and is indicative of the high-calibre scientific, engineering and software talent we have in the region.”
Randox is also showcasing a new test which is a key predictor for cardio-vascular disease and heart attacks. The test identifies a biomarker in the blood called SPLA2; people with high levels of this biomarker can be three times more likely to suffer a severe coronary event.
EuroMedLab 2015, runs from the 22nd- 24th of June at the Palais de Congrés de Paris.
The RX misano is currently unavailable to purchase in Germany